Disorders of carbohydrate metabolism and their relationship with the prevalence of cancer in patients with acromegaly – authors’ own observations

• Authors: Malicka Joanna , Kurowska Maria , Dudzińska Marta , Smoleń Agata , Oszywa-Chabros Anna , Tarach Jerzy
• Languages of publication: EN

Keywords

acromegaly; diabetes; prediabetes; malignancy.

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2016
• Issue: 3
• Pages: 291-293

Contributors

author

Malicka Joanna

author

Kurowska Maria

author

Dudzińska Marta

author

Smoleń Agata

author

Oszywa-Chabros Anna

author

Tarach Jerzy

References

• Kałużny M, Bolanowski M. Acromegaly – a possible cause of diagnostic errors in family doctor’s practice. Fam Med Prim Care Rev 2009; 11(2): 173–178.
• Bolanowski M, Ruchała M, Zgliczyński W, et al. Acromegaly – a novel view of the patient. Polish propos al of diagnostics and therapeutic procedure in the light of recent reports. Endokrynol Pol 2014; 65(4): 326–331, doi: 10.5603/EP.2014.0045.
• Bolanowski M, Kałużny M, Jawiarczyk A. Akromegalia – możliwe trudności diagnostyczne w praktyce lekarza rodzinnego.Fam Med Prim Care Rev 2010; 12(2): 317–319.
• Nomiyama T, Yanase T. Secondary diabetes. Nihon Rinsho 2015; 73(12): 2008–2012 (Abstract).
• Urbani C, Sardella C, Calevro A, et al. Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol 2013; 169(1): 99–108, doi: 10.1530/EJE-13-0032.
• Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009; 30(2): 152–177, doi: 10.1210/er.2008-0027.
• Valea A, Carsote M, Ghervan C, et al. Glycemic profile in patients with acromegaly treated with somatostatin analogue. J Med Life 2015; 8 Spec. Issue: 82–86.
• LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007; 3(3): 302–310.
• Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management.Endocr Rev 2004; 25(1): 102–152.
• Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab 2001; 86(7): 2935–2941.
• Alexopoulou O, Bex M, Kamenicky P, et al. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 1488 patients. Pituitary 2014; 17(1): 81–89, doi: 10.1007/s11102-013-0471-7.
• Wen-Ko C, Szu-Tah C, Feng-Hsuan L, et al. The impact of diabetes mellitus on the survival of patients with acromegaly.Endokrynol Pol 2016; Feb 17, doi: 10.5603/EP.a2016.0031. [Epub ahead of print].
• Zieleniewski W, Michalak R. Akromegalia – niedoceniony problem zdrowotny w praktyce lekarza rodzinnego. Fam Med Prim Care Rev 2011; 13(2): 273–275.
• Bensimon L, Yin H, Suissa S, et al. Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 2014; 25(3): 329–338, doi: 10.1007/s10552-013-0334-6.
• Khandwala HM, McCutcheon IE, Flyvbjerg A, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21(3): 215–244.
• Ruchała M, Szczepanek-Parulska E. Rak tarczycy a akromegalia. Thyroid International 2015; 1: 3–11.